Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Rectal Douche Safety and Acceptability (DREAM-03)
NCT04016233Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenofovir in human immunodeficiency virus infection (HIV), sponsored by Johns Hopkins University. Primary endpoints: Change in Tenofovir Diphosphate concentration at 168 hours, Acceptability of TFV Douche Sequence A and 3 more. Started Jan 2020; status: completed.
02
Drugs
tenofovir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04016233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016233.